Total Flavones

Compound Class	Prenylated flavonol glycosides — the "total flavones" of Epimedium; a distinct subclass of flavonoids
Representative Members	Icariin (the marker and principal active), epimedin A/B/C, icaritin, baohuoside I
Botanical Sources	Epimedium sagittatum and related Epimedium species (horny goat weed; yin yang huo)
Plant Part(s)	Aerial parts (leaf and stem)
Typical Standardisation	Total flavones by HPLC; 50% common. Icariin available separately at 20–40%
Primary Applications	Bone-metabolism and osteoporosis-support formulation; male sexual-function positioning
Claim Strength (Overview)	Emerging — bone evidence is the more substantive; PDE5 inhibition is real but weak relative to pharmaceutical comparators
Buy from Herbuno	Total Flavones 50% Powder (Horny Goat Weed Extract) | Standardized Epimedium sagittatum → Icariin 40% Powder (Horny Goat Weed Extract) | Standardized Epimedium sagittatum →

Name origin: "Total flavones" is a Chinese-pharmacopoeial standardization convention denoting the combined prenylated flavonol glycoside content of Epimedium, rather than a strict chemical class name — the compounds are technically flavonol glycosides bearing prenyl (isoprenoid) side chains, an unusual decoration that distinguishes them from ordinary flavonols. Icariin, the marker compound, takes its name from the genus. The English common name derives from a Chinese folk account of a goatherd observing increased mating activity in goats that had grazed the plant. Traditional use: Epimedium — yin yang huo in Chinese — is a classical kidney-tonifying (bu shen) herb in Traditional Chinese Medicine, and its two principal modern applications map onto that single traditional category with some precision: in TCM theory "the kidneys govern the bones," which underlies its long use in bone and joint conditions, while kidney-yang tonification underlies its use for sexual dysfunction. It is among the most frequently prescribed herbs in Chinese formulas for osteoporosis. Research trajectory: Epimedium research has advanced along the two tracks its tradition implies. The bone track has produced the more substantive evidence, including a 24-month randomized double-blind placebo-controlled trial of Epimedium-derived phytoestrogen flavonoids in late postmenopausal women and multiple systematic reviews. The sexual-function track was energised by the finding that icariin inhibits phosphodiesterase type 5 (PDE5) — the target of sildenafil — though the potency comparison is less flattering than marketing typically implies. Commercial source: Epimedium aerial-part extract standardized to total flavone content is the commercial format; isolated icariin grades are separately available.

---

Evidence for Total Flavones Applications

The bone application has the more substantive evidence base and is arguably the better-founded positioning. A systematic review and meta-analysis of randomized controlled trials evaluating Epimedium and its active components in primary osteoporosis notes that the main active components — icariin, epimedin, and icaritin — regulate bone metabolism through multiple targets, with animal work confirming that icariin has oestrogen-like effects capable of inhibiting RANKL-induced osteoclast bone resorption through oestrogen receptor ERα, and significantly improving bone density and biomechanical properties in ovariectomized rats (Front Pharmacol 2025). That same review is candid that clinical translation remains challenging and that the clinical evidence is scattered relative to the volume of basic research. Claim strength: Emerging.

The PDE5 mechanism is real but should be described with precision rather than allowed to imply pharmaceutical equivalence. Icariin has been demonstrated to exert inhibitory activity against phosphodiesterase type 5 in vitro — the same enzyme targeted by sildenafil — and notably, chemical modification of native icariin by addition of two hydroxyethyl ether moieties enhances its PDE5 inhibitory activity eighty-fold, bringing it near the level observed with sildenafil (Transl Androl Urol 2022). That eighty-fold figure is the honest headline: native icariin’s PDE5 inhibition is roughly two orders of magnitude weaker than a pharmaceutical PDE5 inhibitor, and formulators should not imply otherwise. Claim strength: Emerging.

The oestrogen-receptor activity underlying the bone effect makes icariin a phytoestrogen in functional terms, and this deserves explicit statement because it carries the same caution profile as the isoflavone class. Icariin’s inhibition of osteoclast bone resorption operates through ERα, and Epimedium-derived flavonoids have been described in the clinical literature as phytoestrogens. This is a meaningful safety consideration that is frequently absent from the male-vitality marketing in which this ingredient is most commonly sold — the same compound being positioned for testosterone-adjacent benefit is acting through an oestrogen receptor. Claim strength: Moderate (mechanistic).

The "total flavones" specification aggregates a set of related but non-identical prenylflavonoids — icariin, epimedin A, B, and C, icaritin, and baohuoside I — which differ in glycosylation and, consequently, in absorption. Icariin itself is a glycoside with poor oral bioavailability, and available evidence suggests it is deglycosylated by gut enzymes to icaritin and baohuoside I, which are more lipophilic and may be the more directly active species reaching tissue. A total-flavone percentage therefore reports precursor load rather than delivered active, and the icariin-to-icaritin ratio is a meaningful but rarely specified quality variable. Claim strength: Emerging.

A species-authentication caution specific to this genus: the Epimedium genus contains numerous species — E. sagittatum, E. brevicornum, E. koreanum, E. pubescens among them — and their prenylflavonoid profiles differ. Comparative work has found that different sub-species tested within the same formulation showed broadly similar bone effects, which is reassuring, but the total-flavone content and icariin proportion vary meaningfully between species and commercial substitution is common. Buyers should require the species to be named on the specification rather than accepting "Epimedium spp." Claim strength: Moderate.

---

Dosage & Formulator Specification

Herbuno carries Epimedium sagittatum extract standardized to 50% total flavones, alongside isolated icariin grades at 40% and 20%, and unstandardized horny goat weed extract in powder, water-soluble, and oil-soluble formats. Formulators should be deliberate about whether their claim rests on the whole prenylflavonoid fraction (total flavones) or on icariin specifically, as the two grades deliver different constituent profiles.

Clinical dosing derives largely from Chinese trial and formula practice rather than from Western dose-ranging studies, and formulators should be transparent about that. Bone-focused clinical investigations have used Epimedium flavonoid preparations over extended periods — the referenced postmenopausal bone-loss trial ran 24 months — which is consistent with the slow kinetics of bone remodelling and argues against expecting short-term effects. Sexual-function positioning has considerably less rigorous dose-response data in humans, and given the eighty-fold potency gap between native icariin and pharmaceutical PDE5 inhibitors, formulators should be careful not to imply that a supplement serving delivers a comparable pharmacological effect.

Analytical verification should specify total flavone content by HPLC with icariin quantified separately, and — importantly — with the Epimedium species named. Given that icariin is deglycosylated to more active aglycone forms, characterizing the icariin, epimedin, icaritin, and baohuoside I profile provides a more informative picture than a summed total-flavone figure alone. Species substitution within the genus is common in this trade and should be verified rather than assumed.

Epimedium is generally well tolerated in the clinical literature, with the osteoporosis systematic reviews noting no marked adverse effect signal. Two cautions warrant explicit statement. First, the oestrogen-receptor activity means standard phytoestrogen caution applies — caution for individuals with hormone-sensitive conditions or on hormone-modulating therapy — which is frequently omitted from products positioned around male vitality. Second, the PDE5 inhibitory activity, though weak relative to pharmaceuticals, is mechanistically real, and concurrent use with nitrate medication or with prescription PDE5 inhibitors warrants caution on the same theoretical grounds that govern that drug class.

---

Frequently Asked Questions — Total Flavones

How strong is icariin as a PDE5 inhibitor?
Real but weak. Icariin does inhibit PDE5 — the enzyme sildenafil targets — but the honest measure is this: chemically modifying icariin by adding two hydroxyethyl ether groups increases its PDE5 potency eighty-fold, bringing it near sildenafil's level. That means native icariin is roughly two orders of magnitude weaker, and claims should not imply pharmaceutical equivalence.

Is Epimedium a phytoestrogen?
Functionally, yes — and this is often omitted from the male-vitality marketing. Icariin inhibits osteoclast bone resorption through oestrogen receptor alpha, and Epimedium-derived flavonoids are described in the clinical literature as phytoestrogens. Standard phytoestrogen caution applies for hormone-sensitive conditions, regardless of how the product is positioned.

Which application has better evidence — bone or sexual function?
Bone, by a clear margin. There is a 24-month randomized double-blind placebo-controlled trial in late postmenopausal women, multiple systematic reviews, and a coherent ER-alpha/RANKL mechanism. The sexual-function evidence rests largely on in-vitro PDE5 inhibition and animal work, with the potency gap noted above.

Does "total flavones 50%" tell you the delivered active dose?
Not really. It aggregates icariin, the epimedins, icaritin, and baohuoside I, which differ in glycosylation and absorption. Icariin itself is poorly absorbed and appears to be deglycosylated by gut enzymes to icaritin and baohuoside I — more lipophilic forms that may be the species actually reaching tissue. The figure reports precursor load, not delivered active.

Related compounds: Quercetin, Kaempferol, Genistein, Flavonoids

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery